Drugs / Azelaprag
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06141889 | Nov 2023 → Jan 2024 | — | BioAge Labs, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06515418 | Jun 2024 → Feb 2025 | obesity disorder | BioAge Labs, Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Azelaprag | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06515418 ↗ |
| Known as | BGE-105 | “Oral Azelaprag (BGE-105)” NCT06515418 ↗ |
| Action | Activate | “oral, apelin receptor (APJ) agonist” NCT06141889 ↗ |
| Modality | Small molecule | — CHEMBL4866732 ↗ |
| Route | Oral | “oral, apelin receptor (APJ) agonist” NCT06141889 ↗ |